Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.


http://dlvr.it/T79LGQ

Comments

Popular posts from this blog

Healthy Habits For A Strong Immune System

GLP-1 Drugs Before Bariatric Surgery Can Help People With Extreme Obesity

Understanding Digestive Disorders: Causes, Symptoms, And Treatment Options